Skip to main content
NCBI home page
Neural Regeneration Research logoLink to Neural Regeneration Research
. 2019 Sep 26;15(3):482–490. doi: 10.4103/1673-5374.266064

Neurological recovery and antioxidant effects of resveratrol in rats with spinal cord injury: a meta-analysis

Bao-Ping Xu 1,2,#, Min Yao 1,3,#, Zhen-Jun Li 1,4, Zi-Rui Tian 1,3, Jie Ye 5, Yong-Jun Wang 1,3, Xue-Jun Cui 1,3,*
PMCID: PMC6921347  PMID: 31571660

Abstract

Objective:

To critically assess the neurological recovery and antioxidant effects of resveratrol in rat models of spinal cord injury.

Data sources:

Using “spinal cord injury”, “resveratrol” and “animal experiment” as the main search terms, all studies on the treatment of spinal cord injury in rats by resveratrol were searched for in PubMed, EMBASE, MEDLINE, Web of Science, Science Direct, China National Knowledge Infrastructure, Wanfang, VIP, and SinoMed databases by computer. The search was conducted from their inception date to April 2017. No language restriction was used in the literature search.

Data selection:

The methodological quality of each study was assessed by the initial Stroke Therapy Academic Industry Roundtable recommendations. Two reviewers independently selected studies according to the title, abstract and full text. The risk of bias in the included studies was also evaluated. Meta-analyses were performed with Review Manager 5.3 software.

Outcome measures:

Neurological function was assessed by the Basso, Beattie, and Bresnahan scale score, inclined plane score and Gale’s motor function score. Molecular-biological analysis of antioxidative effects was conducted to determine superoxide dismutase levels, malondialdehyde levels, nitric oxide synthase activity, nitric oxide levels, xanthine oxidase and glutathione levels in spinal cord tissues.

Results:

The methodological quality of the 12 included studies was poor. The results of meta-analysis showed that compared with the control group, resveratrol significantly increased the Basso, Beattie, and Bresnahan scale scores after spinal cord injury (n = 300, mean difference (MD) = 3.85, 95% confidence interval (CI) [2.10, 5.59], P < 0.0001). Compared with the control group, superoxide dismutase levels were significantly elevated (n = 138, standardized mean difference (SMD) = 5.22, 95% CI [2.98, 7.45], P < 0.00001), but malondialdehyde levels were significantly diminished (n = 84, SMD = –3.64, 95% CI [–5.84, –1.43], P = 0.001) in the spinal cord of the resveratrol treatment group.

Conclusions:

Resveratrol promoted neurological recovery and exerted antioxidative effects in rat models of spinal cord injury. The limited quality of the included studies reduces the application of this meta-analysis. Therefore, more high-quality studies are needed to provide more rigorous and objective evidence for the pre-clinical treatment of spinal cord injury.

Keywords: antioxidation, meta-analysis, neurological recovery, pharmacotherapy, rats, resveratrol, spinal cord injury, systematic review

Chinese Library Classification No. R453; R363; R364

Introduction

Spinal cord injury (SCI) is a severe traumatic disease that causes motor and sensory deficits of the body below the damaged section of spinal cord and is associated with high morbidity and mortality (Rogers and Todd, 2016). The economic and psychological costs to patients with SCI can be enormous and their quality of life is often severely curtailed (Oyinbo, 2011). The total global incidence of SCI is approximately 750 per 1,000,000 people (Wyndaele and Wyndaele, 2006) with over 70% of patients undergoing surgical intervention, however, generally with very poor prognosis (Papadopoulos et al., 2002; McKinley et al., 2004). In the last few decades, studies have grappled with the challenge of developing effective agents for preventing or reversing the potentially devastating consequences of SCI. The main ones in current use are methylprednisolone, ganglioside 1, gastrodin and neurotrophic factors (Hollis and Tuszynski, 2011; Adamczak and Hoh, 2016; Caliskan et al., 2016; Du et al., 2016). However, there is an increased risk of respiratory tract infection after methylprednisolone treatment for SCI because of its inhibition of immune function (Bydon et al., 2014), whereas allergies are a common adverse effect for ganglioside 1 (Ates et al., 2006). At present, there are no satisfactory pharmacological therapies for the treatment of SCI because of their side effects and inadequate effectiveness (Hollis and Tuszynski, 2011; Rogers and Todd, 2016). Thus, various other novel strategies for SCI repair have been explored and are the focus of much research.

Resveratrol (3,5,4-trihydroxystilbene), a polyphenol compound, is an abundant drug derived from various herbs (Rocha-Gonzalez et al., 2008). It has a long history in the treatment of cardiovascular and neurological diseases (Lopez et al., 2015). Some previous studies have shown that resveratrol can traverse the blood-brain barrier and provide potential neurological recovery, antioxidant effects and anti-inflammatory effects after SCI (Ates et al., 2006; Liu and Sun, 2009; Tang, 2010; Kesherwani et al., 2013; Du et al., 2016; Sawda et al., 2017; Lange and Li, 2018). Many animal experiments have been designed to evaluate the neurobehavioral recovery and antioxidative effects of resveratrol in SCI. However, there is still controversy about the effectiveness of resveratrol on neurobehavioral recovery in rats with SCI and whether it is due to its antioxidant properties.

Systematic reviews are secondary studies that attempt to collate all the evidence, using a methodical approach to minimize the risk of bias and combine the results of individual studies to produce a better estimate of the effects of a treatment. Therefore, we conducted a systematic review and meta-analysis to assess the neurological recovery and antioxidative effects of resveratrol in rat models of SCI.

Data and Methods

Search strategy

Literature retrieval was conducted from English and Chinese databases, including PubMed, EMBASE MEDLINE, Web of Science, Science Direct, China National Knowledge Infrastructure, Wanfang, VIP, and China Biology Medicine databases. Relevant studies were found using the following search terms “resveratrol-3-sulfate”, “cis-resveratrol”, “trans-resveratrol”, “SRT-501”, “SRT501”, “SRT 501”, “trans-resveratrol-3-O-sulfate”, “3,5,4′-trihydroxystilbene”, “3,4′,5-stilbenetriol”, “resveratrol”, “spinal cord injury”, “spinal cord injuries”, “traumatic spinal cord injury”, “cervical myelopathy”, “cervical spondylosis myelopathy”, “cervical spondylomyelopathy”, “multilevel cervical spondylotic myelopathy”, “cervical spondylotic myelopathy”, and “spinal cord repair”. In addition, the bibliographies of all included articles and important conference papers were searched for additional relevant studies. Retrieval of literature was carried out from the inception dates of the databases to April 2017.

Study selection

Two reviewers (BPX and MY) evaluated each article separately for preliminary screening, according to the title and abstract, then read through the full text for secondary screening. Disagreements were resolved by agreement and discussion with a third party (XJC). No language restriction was used in the literature search, and the search was limited to studies in rats.

Inclusion criteria

Studies were included if they fulfilled all of the following criteria:

  • (1)

    Experimental rat studies that involved at any age or gender with traumatic SCI, including contusion, Allen’s method induced injury, crush and compression injury.

  • (2)

    Controlled SCI experiments with intervention that involved in vivo administration of resveratrol, with no limitations on method of administration, formulation or dosage.

  • (3)

    Outcome of neurological function was evaluated and recorded.

  • (4)

    Biochemical examination of the peroxidation index was included in the analysis.

No language, publication date, or publication status restrictions were imposed.

Exclusion criteria

Studies with one or more of the following conditions were excluded:

  • (1)

    SCI models induced by other causes, such as complete transverse spinal cord injury and spinal cord ischemia/reperfusion injury.

  • (2)

    Conference papers and publications of abstracts only that lacked quantitative data information.

  • (3)

    Repeated publications.

Data extraction

The information was independently extracted from papers using a standardized data extraction tool by two authors (BPX and MY). The following data were extracted: first author, publication year, animal gender, strain and age of rats, number of rats per group treated with resveratrol, animal model of SCI, SCI level, type of intervention, timing of intervention, duration of intervention, daily dose of resveratrol and outcomes of significance to SCI. From these data, the mean ± standard deviation (SD) of every experimental outcome and the numbers of rats in the resveratrol treatment group and SCI group were extracted for meta-analysis. For experiments using multiple dosages of resveratrol compared with the SCI control group, we combined the multiple dosages of the resveratrol treatment groups into a single group for each of the experiments. If neural function evaluation was performed more than once, the last one was used. If the biochemical examinations were performed at different time points, the last outcome indicators that were conducted after SCI were adopted. Last measurements were taken no later than 1 week post SCI. If there were any controversies, we settled the problem by discussion or with the assistance of a third reviewer (XJC).

If the data were missing or incomplete for extraction and analysis, we contacted the authors and requested the additional information. If the data were represented as a graph without a numerical value, numerical values were requested from the authors via email; if a response was not received, digital ruler software was used to estimate numerical values from the graphs with GetData Graph Digitizer 2.24 (http://getdata-graph-digitizer.com/download). If the required data were not presented or obtainable, the study was excluded from the meta-analysis.

Assessment of risk of bias in included studies

The methodological quality of individual studies was assessed according to the initial Stroke Therapy Academic Industry Roundtable (STAIR) recommendations (1999). The STAIR was updated by the STAIR group in 2009, according to the Recommendations for Ensuring Good Scientific Inquiry for America (Fisher et al., 2009). The initial STAIR list includes the following: (1) sample-size calculation, (2) inclusion and exclusion criteria, (3) randomization, (4) allocation concealment, (5) reporting of animals excluded from analysis, (6) blinded assessment of outcome and (7) reporting potential conflicts of interest and study funding. The risks of bias were assessed by two independent researchers (BPX and ZJL) for each study. Bias was assessed as a low or high risk of bias, and ‘‘unclear’’ indicated that the risk of bias was not clear.

Outcome measures

The primary outcomes were evaluation of function (Basso, Beattie, and Bresnahan scale (BBB) score, inclined plane score and Gale’s motor function score) and molecular-biological analysis of antioxidative effects including superoxide dismutase (SOD) levels, malondialdehyde (MDA) levels, reactive oxygen species levels, nitric oxide synthase activity, nitric oxide levels, xanthine oxidase and glutathione levels in the spinal cord tissues.

Statistical analysis

Meta-analysis was conducted using Review Manager, version 5.3 (Cochrane Collaboration, http://community.cochrane.org/help/tools-and-software/revman-5/revman-5-download). Data from all resveratrol groups were pooled to compare with the SCI groups; data were pooled if outcomes were reported by at least three studies and continuous variables were expressed as mean difference (MD) or standardized mean difference (SMD), both with 95% CI. Outcomes including neurological behavior and antioxidative effects were analyzed. If the units of measurement were consistent, MD was used to assess effect size; when the units of measurement were different, SMD was used to assess the effect size. Heterogeneity was tested using chi-square tests: P < 0.1 means heterogeneity, while P > 0.1 means no heterogeneity. The I2 statistic was also used to evaluate the heterogeneity: 0% ≤ I2 < 25% represents no heterogeneity; 25% ≤ I2 < 50% means low heterogeneity; 50% ≤ I2 < 75% reveals moderate heterogeneity; 75% ≤ I2 shows severe heterogeneity. Pooled effect size was estimated using fixed-effects models when there was a lower heterogeneity among the studies, otherwise random-effect models were used. A P < 0.05 was considered statistically significant and the publication biases were judged by funnel plots.

Results

Search results

Among the 212 articles found in the initial search strategy, 111 similar and duplicated studies were removed. Seventy-one articles were ruled out by the titles and abstracts; 30 studies were retained. One study was a conference paper without specific data information (Yang and Luo, 2009); ten did not report any outcome that met the inclusion criteria (Yang and Piao, 2002b, c; Liu et al., 2005, 2013a, b, 2015; Mei et al., 2007; Wang et al., 2012; Mei et al., 2013; Ciftci et al., 2016); and four studies duplicated data (Liu et al., 2011, 2013a; Mei et al., 2012, 2014). Finally, 15 articles (randomized controlled trial studies) met the inclusion criteria (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Liu and Yang, 2009; Zhao et al., 2010, 2017; Mei et al., 2011; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016). Three articles from the same experimental study were conducted as independent experiments (Yang and Piao, 2002a, 2003; Yang, 2003). Therefore, 13 independent studies were included in this study, which contained 15 articles. Of the 15 articles, only one article reported nitric oxide synthase activity, and there were not enough articles to pool data for a meta-analysis (Zhao et al., 2010), so 12 independent studies including 14 articles were chosen for the final meta-analysis after evaluation (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Liu and Yang, 2009; Mei et al., 2011; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017). The flow chart of the study selection is summarized in Figure 1.

Figure 1.

Figure 1

Open in a new tab

Summary of the literature identification and selection process.

CBM: China Biology Medicine; CNKI: China National Knowledge Infrastructure.

Characteristics of included studies

Characteristics of the studies included in this systematic review are shown in Table 1. Of the 14 articles that met the inclusion criteria, most were from China and three were published in English (Yang and Piao, 2002a; Ates et al., 2006; Zhao et al., 2017). All studies were randomized controlled experiments. Sprague-Dawley rats were used in 11 studies (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Liu and Sun, 2009; Liu and Yang, 2009; Mei et al., 2011; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017) and Wistar rats were used in one study (Ates et al., 2006). The total sample sizes for the studies ranged from 24 to 120 (Liu and Sun, 2009; Liu and Yang, 2009; Zhao et al., 2010) and the average sample size was 63. Four studies used only male rats, three studies were conducted using female rats and the other studies had no sex information.

Table 1.

Characteristics of the included studies

Study Country Animals (body weight) Model of SCI Sectionalization and intervention Numbers of per group Treatment timing of resveratrol Sample processing Outcome
Yang and Piao (2002a, 2003); Yang (2003) China SD rats (180–220 g) T8 weight drop model (10 g × 2.5 cm) A: Sham SCI (n = 6)
B: SCI (n = 6)
C: SCI + Res50 (50 mg/kg, i.p.) (n = 6)
D: SCI + Res100 (100 mg/kg, i.p.) (n = 6)
E: SCI + MPSS (100 mg/kg, i.p.) (n = 6)		 1, 24, and 48 hour after SCI 1 h/1 d/2 d Other: MDA, SOD, ROS, ultrastructural examination, western blotting (MAP2, NF, Tau protein)
Mei (2005) China Male SD rats (330 ± 25 g) T8 weight drop model (10 g × 3 cm) A: Blank (n = 2)
B: Sham SCI (n = 6)
C: SCI (n = 18)
D: SCI + Res (100 mg/kg, i.p.) (n = 18)
E: SCI + MPSS (100 mg/kg, i.p.) (n = 18)		 Immediately after SCI 8 h/1 d/3 d Other: SOD, Bcl-2, Bax
Ates et al. (2006) Turkey Male Wistar albino rats (200–250 g) T7–10 weight drop model (5 g × 10 cm) A: Sham SCI (n = 9)
B: SCI (n = 9)
C: SCI + Res (100 mg/kg, i.p.) (n = 9)
D: SCI + MPSS (30 mg/kg, i.p.) (n = 9)
E: SCI + Res (100 mg/kg, i.p.) + MPSS (30 mg/kg, i.p.) (n = 9)
F: SCI + ethanol (2% ethanol 1 mL, i.p.) (n = 9)		 Immediately after SCI 11 d /42 d Behavioristics: inclined plane score, Gale’s motor function score Other: H&E staining, MDA, GSH, NO, XO
Liu and Sun (2009) China SD rats (280–320 g) T8 Allen’s method (10 g × 2.5 cm) A: Sham SCI (n = 8)
B: SCI (n = 8)
C: SCI + Res (100 mg/kg, i.p.) (n = 8)		 Immediately after SCI 3 d Behavioristics: BBB scale Other: H&E staining, MDA, SOD
Liu and Yang (2009) China SD rats (280–320 g) T8 Allen’s method (10 g × 2.5 cm) A: Sham SCI (n = 8)
B: SCI (n = 8)
C: SCI + Res (200 mg/kg, i.p.) (n = 8)		 Immediately after SCI 3 d Behavioristics: BBB scale Other: H&E staining, Nissl staining, TUNEL staining
Mei et al. (2011) China Male SD rats (220 ±30 g) T8 Allen’s method A: SCI (n = 18)
B: SCI + MPSS (100 mg/kg, p.o.) (n = 18)
C: SCI + Res (100 mg/kg, p.o.) (n = 18)		 Immediately after SCI 8 h/1 d/3 d Other: SOD
Wang et al. (2011) China Male SD rats (280–320 g) T8 Allen’s method (10 g × 2.5 cm) A: Sham SCI (n = 16)
B: SCI (n = 16)
C: SCI + Res (200 mg/kg, i.p.) (n = 16)		 Immediately after SCI 6/12 h Behavioristics: BBB scale Other: MDA, SOD, IL-6, TNF-α
Wang (2012) China SD rats T10 Allen’s method A: Sham SCI (n = 16)
B: SCI (n = 32)
C: SCI + SOL (100 mg/kg, i.p.) (n = 32)
D: SCI + Res (100 mg/kg, i.p.) (n = 32)		 Immediately after SCI 4 h /8 h /1 d/ 1.5 d Behavioristics: BBB scale Other: H&E staining, TUNEL staining, SIRT1, IL-1β,IL-6, IL- 10, TNF-α
Liu et al. (2014) China SD rats (280–320 g) T8 Allen’s method (10 g × 2.5 cm) A: Sham SCI (n = 10)
B: SCI (n = 10)
C: SCI + Res50 (50 mg/kg, i.p.) (n = 10)
D: SCI + Res100 (100 mg/kg, i.p.) (n = 10)
E: SCI + Res200 (200 mg/kg, i.p.) (n = 10)
F: SCI + Res300 (300 mg/kg, i.p.) (n = 10)		 Immediately after SCI 3 d Behavioristics: BBB scale Other: H&E staining, Nissl staining
Xiang (2015) China Female SD rats (220–250 g) T10 Allen’s method (10 g × 2.5 cm) A: Blank (n = 24)
B: Sham SCI (n = 24)
C: SCI (n = 24)
D: SCI + Res (50 mg/kg, i.p.) (n = 24)		 Immediately after SCI 3 d Behavioristics: BBB scale Other: TUNEL staining, TTC staining, TNF-α, IL-6, IL-10, NCAM-L, ectrophysiological examination
Li (2016) China Female SD rats (200 g) T9 weight drop model (10 g × 5 cm) A: Sham SCI (n = 6)
B: SCI (n = 20)
C: SCI + Res (200 mg/kg, i.p.) (n = 20)		 1 hour after SCI 7/28 d Behavioristics: BBB scale Other: H&E staining, western bloting (GFAP, P-STAT3, BMP2) immunofluorescence assay (ISCA)
Zhao et al. (2017) China Female SD rats (220–240 g) T9-10 Allen’s method (10 g × 3 cm) A: Sham SCI (n = 17)
B: SCI (n = 17)
C: Res (100 mg/kg, i.p.) (n = 17)		 Immediately after SCI 7 d Behavioristics: BBB scale Other: Nissl staining, H&E staining
Open in a new tab

Bax: Bcl-2 associated X protein; BBB scale: Basso, Beattie, and Bresnahan scale; Bcl-2: B-cell lymphoma-2; BMP2: bone morphogenetic protein 2; GFAP: glial fibrillary acidic protein; GSH: glutathione; H&E: hematoxylin-eosin; IL-1β: interleukin-1β; IL-6: interleukin-6; IL-10: interleukin-10; i.p: intraperitoneal; ISCA: injured spinal cord astrocyte; MAP2: microtubule associated protein 2; MDA: malondialdehyde; MPSS: methylprednisolone sodium succinate; NCAM-L: neural cell adhesion molecule-like protein; NF: neurofilament; NO: nitric oxide; NOS: nitric oxide synthase; po: per os; P-STAT3: phosphorylated signal transducers and activators of transcription-3; Res: resveratrol; ROS: reactive oxygen species; SCI: Spinal cord injury; SD: Sprague-Dawley; SIRT1: silent information regulator 1; SOD: superoxide dismutase; SOL: solutol; Tau protein: microtubule-associated protein tau; TNF-α: tumor necrosis factor-α; TTC staining: triphenyl-2H-tetrazolium chloride staining; TUNEL: transferase mediated dUTP nick end labeling; XO: xanthine oxidase.

All studies used a weight-drop model to induce SCI in rats. The spinal cords of rats in the included studies were exposed aseptically by laminectomy from T7 to T10. Seven studies performed SCI at T8 (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Liu and Sun, 2009; Liu and Yang, 2009; Zhao et al., 2010; Mei et al., 2011; Wang et al., 2011), and no study investigated a cervical or lumbar SCI model. The animals were subjected to an impact on the dorsal surface of the spinal cord, with a range of 25 to 50 g/cm, while two studies gave no detail regarding strike force parameters (Mei et al., 2011; Wang, 2012).

In most studies resveratrol was administered to SCI rats immediately afterwards, either intraperitoneally (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Liu and Yang, 2009; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017) or orally (Mei et al., 2011), at doses ranging from 50 to 300 mg/kg (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Liu and Yang, 2009; Mei et al., 2011; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017). The positive control medication was methylprednisolone sodium succinate (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Zhao et al., 2010; Mei et al., 2011; Liu et al., 2014; Xiang, 2015). All studies reported the outcomes by evaluation of function or biochemical analysis, and the BBB test was used in rats with traumatic SCI 12 hours to 28 days after injury. Some studies also used immunohistochemical analysis and electrophysiological examination to detect features of SCI (Yang and Piao, 2002a, 2003; Yang, 2003; Ates et al., 2006; Liu and Sun, 2009; Liu and Yang, 2009; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017).

Bias analysis of included studies

The risks of bias for all 12 independent studies, included in the 14 articles, are shown in Table 2. Overall, the methodological quality of the studies was not high. None of the studies described a sample-size calculation, randomization method, allocation concealment or potential conflicts of interest or study funding. Eight studies described the inclusion and exclusion criteria (Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Zhao et al., 2010; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Li, 2016) and only one study described the animals excluded from analysis (Ates et al., 2006). Blinded assessment of the outcome was described in two studies (Wang et al., 2011; Liu et al., 2014). Only two studies contained a statement of potential conflicts of interest (Li, 2016; Zhao et al., 2017).

Table 2.

Assessment of risk of bias in included studies

Study Sample size calculation Inclusion and exclusion criteria Randomization Allocation concealment Reporting of animals excluded from analysis Blinded assessment of outcome Reporting potential conflicts of interest and study funding
Yang (2003); Yang and Piao (2002a, 2003) Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Mei (2005) Unclear Low Unclear Unclear Unclear Unclear Unclear
Ates et al.(2006) Unclear Unclear Unclear Unclear Low Unclear Unclear
Liu and Sun (2009) Unclear Low Unclear Unclear Unclear Unclear Unclear
Liu and Yang (2009) Unclear Low Unclear Unclear Unclear Unclear Unclear
Mei et al. (2011) Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Wang et al. (2011) Unclear Low Unclear Unclear Unclear Low Unclear
Wang (2012) Unclear Low Unclear Unclear Unclear Unclear Unclear
Liu et al. (2014) Unclear Low Unclear Unclear Unclear Low Unclear
Xiang (2015) Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Li (2016) Unclear Low Unclear Unclear Unclear Unclear Low
Zhao et al. (2017) Unclear Unclear Unclear Unclear Unclear Unclear Low
Open in a new tab

Meta-analysis of neurological recovery and antioxidative effects of resveratrol

Assessment of neurological recovery effect of resveratrol

The meta-analysis of BBB score data from eight studies showed a significant neurological recovery effect with resveratrol (Liu and Sun, 2009; Liu and Yang, 2009; Wang et al., 2011; Wang, 2012; Liu et al., 2014; Xiang, 2015; Li, 2016; Zhao et al., 2017). The BBB score significantly increased after resveratrol intervention (8 studies, n = 300, MD = 3.85, 95% CI [2.10 to 5.59], P < 0.0001; Figure 2) in a random-effects model because of the high heterogeneity (I2 = 99%, P < 0.00001). In addition, dose subgroup analysis was not performed as fewer studies were included. Significant heterogeneities (I2 > 90%) still existed in the sensitivity analysis, and there was no significant difference in the before and after the sensitivity analysis.

Figure 2.

Figure 2

Open in a new tab

Forest plot for the effects of resveratrol intervention on Basso, Beattie, and Bresnahan scale scores in rats with SCI (random-effects model).

CI: Confidence interval; Res: resveratrol; SCI: spinal cord injury; SD: standard deviation.

One study (Ates et al., 2006) measured neurological recovery using the inclined plane score and Gale’s motor function score. Significant increases of the mean inclined plane test results and motor function scores were found compared with the SCI control group (P < 0.05). The resveratrol group also revealed a significantly greater improvement on the inclined plane test than the group that received methylprednisolone sodium succinate therapy (Ates et al., 2006).

Assessment of antioxidative effects of resveratrol

Antioxidative effects were measured in nine articles (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Ates et al., 2006; Liu and Sun, 2009; Zhao et al., 2010; Mei et al., 2011; Wang et al., 2011). Five studies measured SOD levels after SCI (Yang and Piao, 2002a, 2003; Yang, 2003; Mei, 2005; Liu and Sun, 2009; Mei et al., 2011; Wang et al., 2011). Heterogeneity was significantly high in this group of studies (heterogeneity χ2 = 38.64, P < 0.0001, I2 = 90%; Figure 3). SOD levels were significantly higher in the resveratrol group compared with the SCI group (five studies, n = 138, SMD = 5.22, 95% CI [2.98, 7.45], P < 0.00001; Figure 3) using a random-effects model.

Figure 3.

Figure 3

Open in a new tab

Forest plot for the effects of resveratrol intervention on superoxide dismutase levels in rats with SCI (random-effects model).

Superoxide dismutase meta-analysis after SCI. CI: Confidence interval; Res: resveratrol; SCI: spinal cord injury; SMD: standardized mean difference.

Four studies measured MDA levels after SCI (Yang and Piao, 2002a, 2003; Yang, 2003; Ates et al., 2006; Liu and Sun, 2009; Wang et al., 2011) and found that MDA levels were significantly lower in the resveratrol group than in the SCI groups using a random-effects model (four studies, n = 84, SMD = −3.64, 95% CI [–5.84 to –1.43], P = 0.001; Figure 4).

Figure 4.

Figure 4

Open in a new tab

Forest plot for the effects of resveratrol intervention on malondialdehyde levels in SCI rats (random-effects model).

CI: Confidence interval; Res: resveratrol; SCI: spinal cord injury; SMD: standardized mean difference.

Reactive oxygen species levels were measured in one study after SCI; the post-traumatic reactive oxygen species level in the injured cord was significantly lower in the resveratrol group compared with the SCI group (P < 0.05) (Yang and Piao, 2002a, 2003; Yang, 2003). Only one study (Ates et al., 2006) tested for other antioxidative measures and reported that nitric oxide and xanthine oxidase were significantly lower, and glutathione levels were higher in the resveratrol group than in the SCI group (P < 0.05).

Publication bias

Funnel plots of publication bias for BBB score, SOD levels and MDA levels are assessed (Figure 5). The asymmetries found in the funnel plots indicated the possibility of publication bias.

Figure 5.

Figure 5

Open in a new tab

Asymmetries found in the funnel plots indicated the possibility of publication bias.

Funnel plots of publication bias for Basso, Beattie, and Bresnahan scale scores (A), superoxide dismutase (B) and malondialdehyde levels (C).

Discussion

Summary of main results

This is the first meta-analysis to evaluate the neurological recovery and antioxidative effects of resveratrol in rat models of SCI. Our study found that administration of resveratrol after SCI could provide a beneficial impact on the neurological recovery and the antioxidant activity in rats. Compared with SCI groups, a significant elevation in the BBB score was detected and resveratrol treatment significantly increased serum SOD levels and decreased serum MDA levels in rats after SCI in the resveratrol groups. Despite our selection criteria, the general quality of the included articles was not high; no study was considered to be of high quality as the sample-size calculation method, randomization and allocation concealment mechanisms were not all reported in every one of the included studies.

Strengths and limitation of evidence

The pathophysiological mechanism of secondary SCI is still not clear, but oxidative stress reactions play a significant role in the physiological pathology and subsequent functional neurological recovery. Our quantitative analysis of previous studies demonstrated improved neurological recovery and antioxidative effects of resveratrol in rats with SCI. A fundamental assumption is that the results of animal studies, if performed well enough, would be meaningful in humans and lead to promising neurological recovery drugs for clinical practice. However, there are several sources of bias in this systematic review.

A reliable conclusion of a meta-analysis is based on the quantity and quality of the included studies. Where we were able to obtain the STAIR assessment of quality from the included studies, it was judged to be of low quality. There are several limitations of this systematic review. First, among the 15 articles selected, only 3 articles were published in English, the rest were written in Chinese or from China and, more importantly, we did not know whether all the papers were widely peer-reviewed before publication. In addition, the limited number of articles was also a major limitation of this review. Many of the included studies were published some time ago. Nearly half of the included articles were published pre-2010. We found the quality of the included articles was poor, lacking adherence to applicable animal research guidelines. Second, none of the included studies mentioned the random allocation of rats to groups, and it has been shown that studies not using random allocation are more likely to report a positive effect than studies that do (Bebarta et al., 2003). The measurement methods for SOD and MDA levels were different in different studies and the measurement units also varied. Although we use standardized mean difference values to reduce the statistical effect size, the bias was still not completely eliminated and this is also an important factor influencing the quality of the research. None of the studies reported sample-size calculations and the number of included studies was relatively small, potentially producing large positive bias effects. Therefore, the confidence in our analysis is limited by the quality of the original studies; the true effect is likely to be substantially different from the estimated effect.

Resveratrol exists in two isoforms, cis-resveratrol and trans-resveratrol. Most recent studies focus on the trans-isomer, which has been suggested to be the principal one responsible for the neurological recovery and antioxidative effects (Yanez et al., 2006; Mikulski et al., 2010; Wang and Chatterjee, 2017). Trans-resveratrol is readily converted to the cis- isoform under ultraviolet or light, and this conversion reduces the potency and therapeutic effects of resveratrol (Delmas et al., 2011). A parameter of cis- or trans- isoform of resveratrol usage in meta-analysis should be considered; however, none of the 15 articles included in this study mentioned isoforms of resveratrol. The administration of the resveratrol is also a critical factor because the bioavailability of oral resveratrol, hypodermic and intraperitoneal injection of resveratrol is poor (Rotches-Ribalta et al., 2012). Another important factor in determining heterogeneity is the source of financial support. The funded organization should be disclosed in the article; however, eight of the studies included in our analysis did not disclose detailed information of funding. The outcomes targeted in this review were specific to rat models that used a weight-drop model to induce SCI and did not include other animal models or other SCI models, thus the therapeutic effects of resveratrol by neurological recovery and antioxidation shown in this review may not apply to all species and SCI models. Although the SCI model is widely used by different labs, it can still vary and relies heavily on the technique of the surgeon. Furthermore, the BBB locomotor score is a subjective assessment method, and the results varied in the different studies, which will make it more difficult to interpret the conclusions. All these aspects suggest that there is a high risk of bias. Unfortunately it will inevitably affect the credibility of the conclusions for this paper.

Potential mechanism of neurological recovery and antioxidative effects

Secondary injury, including neuronal apoptosis and oxidative stress responses, occurs after the initial SCI and leads to further neurological damage (Liu et al., 2016; Kong and Gao, 2017; Simon et al., 2019). It plays an important role in secondary pathology following SCI (Cheng et al., 2019; Rodemer and Selzer, 2019; Sharma et al., 2019). Some studies found that expression of Bcl-2 genes, associated with the inhibition of apoptosis of neuronal cells rose significantly, and neuronal apoptosis were significantly inhibited, after treatment of SCI rats with resveratrol (Zhang et al., 2012; Kong and Gao, 2017; Zhao et al., 2017). In addition, BBB scores increased significantly after resveratrol intervention compared with the SCI group (Zhao et al., 2017); indicating that resveratrol administration significantly improved the recovery of locomotor function in rats with SCI. Many free radicals are produced after SCI (Bains and Hall, 2012; Hall et al., 2016) causing lipid oxidative degradation, thus SOD and MDA levels were used as indices of oxidative damage (Oumi et al., 2017). Previous studies found that resveratrol is a biological antioxidant that can reduce secondary oxidative stress-induced cell damage after SCI by increasing serum SOD levels and decreasing serum MDA levels (Ates et al., 2006; Fu et al., 2016). Resveratrol may act by removing free radicals. This potential mechanism of neurological recovery and antioxidative effects suggests that resveratrol could be a potential preventive and therapeutic agent for neurological disease.

Conclusions

Based on the results of this meta-analysis, we demonstrated that resveratrol intervention could improve neurological recovery and antioxidative effects in rat models of SCI. A possible mechanism is that it scavenges free radicals, decreasing the levels of MDA and increasing SOD levels, thereby inhibiting neuronal apoptosis.

The results of this meta-analysis must be interpreted and applied with an appropriate degree of caution because some factors such as the poor methodological quality of the studies and possible publication bias may undermine the validity of the positive findings. Even so, resveratrol could be a promising drug to treat SCI. In the future, it deserves a larger study that takes into account the design features recommended in the discussion of this meta-analysis.

Footnotes

Conflicts of interest: The authors have no conflicts of interest to declare.

Financial support: This work was supported by the National Natural Science Foundation of China, No. 81873317 (to XJC), No. 81704096 (to MY), No. 81603635 (to JY); a grant from the Municipal Science and Technology Commission of Shanghai-TCM Key Project in China, No. 16401970100 (to YJW); a grant from the Shanghai TCM Medical Center of Chronic Disease in China, No. 2017ZZ01010 (to YJW); the National Thirteenth Five-Year Science and Technology Major Special Project for New Drug Innovation and Development in China, No. 2017ZX09304001 (to YJW). The funding sources had no role in study conception and design, data analysis or interpretation, paper writing or deciding to submit this paper for publication.

Reporting statement: This study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.

Biostatistics statement: The statistical methods of this study were reviewed by the biostatistician of Shanghai University of Traditional Chinese Medicine, China.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Funding: This work was supported by the National Natural Science Foundation of China, No. 81873317 (to XJC), No. 81704096 (to MY), No. 81603635 (to JY); a grant from the Municipal Science and Technology Commission of Shanghai-TCM Key Project in China, No. 16401970100 (to YJW); a grant from the Shanghai TCM Medical Center of Chronic Disease in China, No. 2017ZZ01010 (to YJW); the National Thirteenth Five-Year Science and Technology Major Special Project for New Drug Innovation and Development in China, No. 2017ZX09304001 (to YJW).

C-Editor: Zhao M; S-Editors: Wang J, Li CH; L-Editors: Dawes EA, Raye W, Qiu Y, Song LP; T-Editor: Jia Y

References

  • 1.Adamczak SE, Hoh DJ. Steroids and spinal cord injury-a global dilemma. World Neurosurg. 2016;90:641–643. doi: 10.1016/j.wneu.2016.01.047. [DOI] [PubMed] [Google Scholar]
  • 2.Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Kocak A, Yologlu S, Turkoz Y. Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta Pharmacol Sin. 2006;27:1317–1325. doi: 10.1111/j.1745-7254.2006.00416.x. [DOI] [PubMed] [Google Scholar]
  • 3.Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta. 2012;1822:675–684. doi: 10.1016/j.bbadis.2011.10.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bebarta V, Luyten D, Heard K. Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med. 2003;10:684–687. doi: 10.1111/j.1553-2712.2003.tb00056.x. [DOI] [PubMed] [Google Scholar]
  • 5.Bydon M, Lin J, Macki M, Gokaslan ZL, Bydon A. The current role of steroids in acute spinal cord injury. World Neurosurg. 2014;82:848–854. doi: 10.1016/j.wneu.2013.02.062. [DOI] [PubMed] [Google Scholar]
  • 6.Caliskan M, Simsek S, Vural SA, Besalti O. Comparison of etanercept, etomidate and erythropoietin and their combinations in experimentally-induced spinal cord injury. Turk Neurosurg. 2016;26:930–936. doi: 10.5137/1019-5149.JTN.14036-15.1. [DOI] [PubMed] [Google Scholar]
  • 7.Cheng JP, Li H, Li XJ. Extract of piper auritum can alleviate oxidative stress and inflammation of rat models of acute spinal cord injury. Zhongguo Zuzhi Gongcheng Yanjiu. 2019;23:5010–5016. [Google Scholar]
  • 8.Ciftci U, Delen E, Vural M, Uysal O, Turgut Cosan D, Baydemir C, Doganer F. Efficiacy of resveratrol and quercetin after experimental spinal cord injury. Ulus Travma Acil Cerrahi Derg. 2016;22:423–431. doi: 10.5505/tjtes.2016.44575. [DOI] [PubMed] [Google Scholar]
  • 9.Delmas D, Aires V, Limagne E, Dutartre P, Mazue F, Ghiringhelli F, Latruffe N. Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci. 2011;1215:48–59. doi: 10.1111/j.1749-6632.2010.05871.x. [DOI] [PubMed] [Google Scholar]
  • 10.Du F, Wang X, Shang B, Fang J, Xi Y, Li A, Diao Y. Gastrodin ameliorates spinal cord injury via antioxidant and anti-inflammatory effects. Acta Biochim Pol. 2016;63:589–593. doi: 10.18388/abp.2016_1272. [DOI] [PubMed] [Google Scholar]
  • 11.Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244–2250. doi: 10.1161/STROKEAHA.108.541128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fu S, Lv R, Wang L, Hou H, Liu H, Shao S. Resveratrol, an antioxidant, protects spinal cord injury in rats by suppressing MAPK, pathway. Saudi J Biol Sci. 2016;25:259–266. doi: 10.1016/j.sjbs.2016.10.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hall ED, Wang JA, Bosken JM, Singh IN. Lipid peroxidation in brain or spinal cord mitochondria after injury. J Bioenerg Biomembr. 2016;48:169–174. doi: 10.1007/s10863-015-9600-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hollis ER, 2nd, Tuszynski MH. Neurotrophins: potential therapeutic tools for the treatment of spinal cord injury. Neurotherapeutics. 2011;8:694–703. doi: 10.1007/s13311-011-0074-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kesherwani V, Atif F, Yousuf S, Agrawal SK. Resveratrol protects spinal cord dorsal column from hypoxic injury by activating Nrf-2. Neuroscience. 2013;241:80–88. doi: 10.1016/j.neuroscience.2013.03.015. [DOI] [PubMed] [Google Scholar]
  • 16.Kong X, Gao J. Macrophage polarization: a key event in the secondary phase of acute spinal cord injury. J Cell Mol Med. 2017;21:941–954. doi: 10.1111/jcmm.13034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lange KW, Li S. Resveratrol, pterostilbene and dementia. Biofactors (Oxford, England) 2018;44:83–90. doi: 10.1002/biof.1396. [DOI] [PubMed] [Google Scholar]
  • 18.Li P. Dalian, China: Dalian Medical University; 2016. Resveratrol via STAT3/BMP pathway regulated astrocyte activation to facilitate recovery after spinal cord injury. [Google Scholar]
  • 19.Liu C, Shi Z, Fan L, Zhang C, Wang K, Wang B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res. 2011;1374:100–109. doi: 10.1016/j.brainres.2010.11.061. [DOI] [PubMed] [Google Scholar]
  • 20.Liu CJ, Wang BJ, Zhang C. Dose-effect relationship of the protective effect of resveratrol on acute spinal cord injury in rats. Xi’an Jiaotong Daxue Xuebao. 2014;35:475–480. [Google Scholar]
  • 21.Liu CJ, Bi WC, Zhang C, Shi ZB, Wang KZ. Effect of resveratrol on inflammatory reaction after spinal cord injury in rats. Xi’an Jiaotong Daxue Xuebao. 2013a;34:779–784. [Google Scholar]
  • 22.Liu CJ, Yan CH, Shi B. Effect of resveratrol injection on apoptosis of nerve cells and signal transduction pathways after spinal cord injuries in rats. Shandong Tiyu Xueyuan Xuebao. 2013b;29:46–51. [Google Scholar]
  • 23.Liu CJ, Sun CY. Protective effect of Resveratrol on spinal cord injury in rats. Disi Junyi Daxue Xuebao. 2009;30:1199–1201. [Google Scholar]
  • 24.Liu CJ, Yang K. Effect of resveratrol on motor function and cells apoptosis after acute spinal cord injury in rats. Xi’an Tiyu Daxue Xuebao. 2009;26:570–574. [Google Scholar]
  • 25.Liu J, Yi L, Xiang Z, Zhong J, Zhang H, Sun T. Resveratrol attenuates spinal cord injury-induced inflammatory damage in rat lungs. Int J Clin Exp Pathol. 2015;8:1237–1246. [PMC free article] [PubMed] [Google Scholar]
  • 26.Liu JM, Wang FC, Zhou YJ, Mu L, Hou SK, Hao LN, Zhang ZT. Effect of electroacupuncture stimulation on apoptosis of nerve cells in a rat model of spinal cord contusion. Zhongguo Zuzhi Gongcheng Yanjiu. 2016;20:616–621. [Google Scholar]
  • 27.Liu SQ, Mei HJ, Liu J, Hao P. Effects of resveratrol on the expression of Bcl-2 and Bax in rats with early spinal cord injury. Zhongguo Linchuang Kangfu. 2005;9:130–132. [Google Scholar]
  • 28.Lopez MS, Dempsey RJ, Vemuganti R. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int. 2015;89:75–82. doi: 10.1016/j.neuint.2015.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.McKinley W, Meade MA, Kirshblum S, Barnard B. Outcomes of early surgical management versus late or no surgical intervention after acute spinal cord injury. Arch Phys Med Rehabil. 2004;85:1818–1825. doi: 10.1016/j.apmr.2004.04.032. [DOI] [PubMed] [Google Scholar]
  • 30.Mei H, Liu Y, Zheng X. Effects of resveratrol on toxidation, anti-oxidation after spinal cord injury in rats. Shengwu Guke Cailiao yu Linchuang Yanjiu. 2012;9:47–49. [Google Scholar]
  • 31.Mei H, Liu Y, Zhang H. Effect of intragastric resveratrol on the activity of the myeloperoxidase and cytochrome C oxidase in inflammatory reaction after the spinal cord injury in rats. Zhongguo Guzhi Shusong Zazhi. 2014;20:676–679. [Google Scholar]
  • 32.Mei H, Liu Y, Tian H, Zhang H. Inhibition effect of resveratrol on the myelonic neuronal apoptosis in rats with spinal cord injury. Wuhan Daxue Xuebao Yixueban. 2013;34:832–835. [Google Scholar]
  • 33.Mei HJ. Wuhan, China: Wuhan University; 2005. The experimental study on the protective effect of resveratrol in the forepart spinal cord injury. [Google Scholar]
  • 34.Mei HJ, Zhang SY, Liu SQ, Liu J. Effects of resveratrol on the myelonic neuronal apoptosis in the forepart of spinal cord injury in rats. Wuhan Daxue Xuebao Yixueban. 2007;28:226–229. [Google Scholar]
  • 35.Mei HJ, Liu Y, Zhen XL, Wang HZ, Wang CM. Effects of resveratrol on the expression of cytochrome c and superoxide dismutase in the early periodof spinal cord injury of rats. Zhongguo Zhongyi Gushangke Zazhi. 2011;19:11–13. [Google Scholar]
  • 36.Mikulski D, Gorniak R, Molski M. A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. Eur J Med Chem. 2010;45:1015–1027. doi: 10.1016/j.ejmech.2009.11.044. [DOI] [PubMed] [Google Scholar]
  • 37.Oumi T, Nozato T, Sakakibara A, Nomoto H, Ohno M, Takahashi Y, Ashikaga T, Satoh Y, Isobe M. Malondialdehyde-modified low density lipoprotein as oxidative-stress marker in vasospastic angina patients. Int Heart J. 2017;58:335–343. doi: 10.1536/ihj.16-455. [DOI] [PubMed] [Google Scholar]
  • 38.Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars) 2011;71:281–299. doi: 10.55782/ane-2011-1848. [DOI] [PubMed] [Google Scholar]
  • 39.Papadopoulos SM, Selden NR, Quint DJ, Patel N, Gillespie B, Grube S. Immediate spinal cord decompression for cervical spinal cord injury: feasibility and outcome. J Trauma. 2002;52:323–332. doi: 10.1097/00005373-200202000-00019. [DOI] [PubMed] [Google Scholar]
  • 40.Rocha-Gonzalez HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther. 2008;14:234–247. doi: 10.1111/j.1755-5949.2008.00045.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rodemer W, Selzer ME. Role of axon resealing in retrograde neuronal death and regeneration after spinal cord injury. Neural Regen Res. 2019;14:399–404. doi: 10.4103/1673-5374.245330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Rogers WK, Todd M. Acute spinal cord injury. Best Pract Res Clin Anaesthesiol. 2016;30:27–39. doi: 10.1016/j.bpa.2015.11.003. [DOI] [PubMed] [Google Scholar]
  • 43.Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res. 2012;66:375–382. doi: 10.1016/j.phrs.2012.08.001. [DOI] [PubMed] [Google Scholar]
  • 44.Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer’s disease. Ann N Y Acad Sci. 2017;1403:142–149. doi: 10.1111/nyas.13431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sharma S, Goel SA, Sharma S, Chhabra HS. Polyetheretherketone cages used in anterior cervical discectomy and fusion surgery: a meta-analysis. Clin Trials Orthop Disord. 2019;4:29–33. [Google Scholar]
  • 46.Simon F, Floros N, Ibing W, Schelzig H, Knapsis A. Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system. Neural Regen Res. 2019;14:1309–1312. doi: 10.4103/1673-5374.253507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752–2758. doi: 10.1161/01.str.30.12.2752. [DOI] [PubMed] [Google Scholar]
  • 48.Tang BL. Resveratrol is neuroprotective because it is not a direct activator of Sirt1-A hypothesis. Brain Res Bull. 2010;81:359–361. doi: 10.1016/j.brainresbull.2009.12.007. [DOI] [PubMed] [Google Scholar]
  • 49.Wang F, Chatterjee S. Dominant carbons in trans- and cis-resveratrol isomerization. J Phys Chem B. 2017;121:4745–4755. doi: 10.1021/acs.jpcb.7b02115. [DOI] [PubMed] [Google Scholar]
  • 50.Wang GS, Wang F, Qiang H, Qaing J. The protective and anti-oxidative stress effect of resveratrol on spinal cord injury in rats. Shanxi Zhongyi. 2011;32:111–113. [Google Scholar]
  • 51.Wang X, Sun T, Li F, Zhang Z, Liu J. The influence of SIRT1 on the inflammation in rat acute spinal cord injury. Zhonghua Linchang Yishi Zazhi (Electronic Edition) 2012;6:84–87. [Google Scholar]
  • 52.Wang XK. Taiyuan, China: Shanxi Medical University; 2012. The influence of SIRTl on the neurological recovery after spinal cord injury in rats. [Google Scholar]
  • 53.Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord. 2006;44:523–529. doi: 10.1038/sj.sc.3101893. [DOI] [PubMed] [Google Scholar]
  • 54.Xiang ZM. Chongqing, China: Third Military Medical University; 2015. The role and mechanism of resveratrol to protect the spinal cord and the distant organs after spinal cord injury in rats. [Google Scholar]
  • 55.Yanez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun. 2006;344:688–695. doi: 10.1016/j.bbrc.2006.03.190. [DOI] [PubMed] [Google Scholar]
  • 56.Yang YB. Guangzhou: First Military Medical University, China; 2003. The neuroprotection of resveratrol on spinal cord injury in rats. [Google Scholar]
  • 57.Yang Y, Luo J. Yokohama, Japan: 2009. Resveratrol reduces the expression of VCAM-1 and ICAM-1 after spinal cord injury in rats. Paper presented at: 82nd Annual Meeting of the Japanese-Pharmacological-Society 2009. [Google Scholar]
  • 58.Yang YB, Piao YJ. Inhibition of resveratral on lipid peroxidative reaction and reactive oxygen species of early experimental rat spinal cord injury. Zhongguo Linchuang Yaolixue yu Zhiliaoxue. 2002a;7:193–195. [Google Scholar]
  • 59.Yang YB, Piao YJ. Effects of resveratrol on secondary spinal cord edema and activity of lactic dehydrogenase and ATPase in experimental spinal cord injury of rats. Acta Pharmacol Sin. 2002b;18:539–543. [Google Scholar]
  • 60.Yang YB, Piao YJ. Effects of resveratrol on Ca2+, Mg(2+)-ATPase activities after spinal cord trauma in rats. Zhong Yao Cai. 2002c;25:882–885. [PubMed] [Google Scholar]
  • 61.Yang YB, Piao YJ. Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta Pharmacol Sin. 2003;24:703–710. [PubMed] [Google Scholar]
  • 62.Zhang L, Gan W, An G. Influence of Tanshinone IIa on heat shock protein 70, Bcl-2 and Bax expression in rats with spinal ischemia/reperfusion injury. Neural Regen Res. 2012;7:2882–2888. doi: 10.3969/j.issn.1673-5374.2012.36.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zhao H, Chen S, Gao K, Zhou Z, Wang C, Shen Z, Guo Y, Li Z, Wan Z, Liu C, Mei X. Resveratrol protects against spinal cord injury by activating autophagy and inhibiting apoptosis mediated by the SIRT1/AMPK signaling pathway. Neuroscience. 2017;348:241–251. doi: 10.1016/j.neuroscience.2017.02.027. [DOI] [PubMed] [Google Scholar]
  • 64.Zhao XM, Liu SQ, Mei HJ, Zhang N, Yong-Gang MA, Deng M. Effects of resveratrol on activity of MPO and NOS after acute spinal cord injury of rats. Kexue Jishu yu Gongcheng. 2010;10:3455–3458. [Google Scholar]

Articles from Neural Regeneration Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES